With new approaches coming down the pike and Hemlibra (emicizumab, Roche Holdings AG) due for a potentially wider label in a month or so, Bayer AG's win with longer half-life Jivi (antihemophilic factor [recombinant] pegylated-aucl) makes for an even more competitive hemophilia A space.